scholarly journals Integrative Medicine Program- MD Anderson Cancer Center

2012 ◽  
Vol 7 ◽  
pp. 19
Author(s):  
Richard T Lee
Keyword(s):  
Clinical Outcomes ◽  
Integrative Medicine ◽  
Clinical Care ◽  
Cancer Center ◽  
Future Research ◽  
Clinical Services ◽  
Care Plans ◽  
Md Anderson ◽  
Integrative Medicine Program ◽  
Group Programs

The Integrative Medicine Program at MD Anderson Cancer Center was first established in 1998.  Our mission is to empower patients with cancer and their families to become active partners in their own physical, psycho-spiritual, and social health through personalized education and evidenced-based clinical care to optimize health, quality of life, and clinical outcomes across the cancer continuum.  The program consists of three main components: clinical care, research, and education.  The Integrative Medicine Center provides clinical services to patients through individual and group programs.  The clinical philosophy of the center is to work collaboratively with the oncology teams to build comprehensive and integrative care plans that are personalized, evidence-based, and safe with the goal of improving clinical outcomes.  The individual services comprise of integrative oncology consultation, acupuncture, meditation, music therapy, nutrition, and oncology massage.  The center also provides a variety of group programs including meditation, yoga, tai chi, cooking classes and others.  Over the past 13 years, over 70,000 patients and families have participated in services and programs offered by the center.  The research portfolio focuses on three main areas: mind-body interventions, acupuncture, and meditation.  This lecture will focus on providing an overview of the Integrative Medicine Program at MD Anderson with a focus on the clinical services provided.  Participants will learn about the integrative clinical model and how this is applied to the care of cancer patients at MD Anderson Cancer Center.  Current and future research topics will be discussed as well as patient cases.

scholarly journals Research Trends of Acupuncture Therapy on Cancer Over the Past Two Decades: A Bibliometric Analysis

2020 ◽  
Vol 19 ◽  
pp. 153473542095944
Author(s):  
Jing Guo ◽  
Lixia Pei ◽  
Lu Chen ◽  
Hao Chen ◽  
Dongmei Gu ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Acupuncture Therapy ◽  
Supportive Care ◽  
Bibliometric Analysis ◽  
Integrative Medicine ◽  
Clinical Studies ◽  
Current Status ◽  
Cancer Center ◽  
Future Research ◽  
The Past

Purpose: Acupuncture has been used for managing cancer-related symptoms. However, there are still few studies concerning the overall trends in acupuncture therapy on cancer based on bibliometric analysis. This study aims to demonstrate the current status and trends in this field over the past 2 decades. Methods: Articles were retrieved from the Web of Science from 2000 to 2019. CiteSpace was used for co-authorship network of countries/institutions, dual-map analysis, and detecting the keywords with citation bursts. VOSviewer was used to construct networks based on co-authorship and co-citation analysis of authors, and co-occurrence of keywords. Results: A total of 927 articles and reviews were included in the final analysis. The number of publications has steadily increased with some fluctuations among years. The country and institution contributing most to this field are the USA and Memorial Sloan Kettering Cancer Center. Mao JJ was the most productive author and Molassiotis A ranked first in the cited authors. The co-occurrence analysis revealed 5 clusters (including “clinical trials,” “clinical studies on chemotherapy/radiation-induced symptoms,” “CAM therapy for cancer,” “clinical studies on vasomotor symptoms,” and “systematic reviews”). Most recent keyword bursts were “neuropathic pain,” “arthralgia,” “prevention,” “supportive care,” and “integrative medicine”. Conclusions: The annual publication output would increase rapidly in the next decade, which shows a promising future in this research field. Future research hotspots would focus on the role of acupuncture in neuropathic pain, arthralgia, prevention, supportive care, and integrative medicine.

Association of the GATA3 rs3824662A allele with clinical outcomes in adult patients with adult B-ALL.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 7023-7023
Author(s):  
Paul B. Koller ◽  
Hagop M. Kantarjian ◽  
Elias Jabbour ◽  
Sherry A. Pierce ◽  
Kathryn Roberts ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Lymphoblastic Leukemia ◽  
White Blood Count ◽  
Cancer Center ◽  
P Value ◽  
Free Survival ◽  
Genotype Group ◽  
Adults And Children ◽  
Md Anderson

7023 Background: Inherited GATA3 variants (rs3824662) have been described in higher frequency in both adults and children with Ph-like acute lymphoblastic leukemia (Ph-like ALL) (Perez-Andreu, Nat Genetics 2013; Jain, ASH 2017). The clinical outcomes of Ph-like ALL are well known, and as we have previously described, it as a high-risk subtype of ALL in both children and adults (Roberts, NEJM 2014; Roberts, JCO 2017; Jain, Blood 2017). However, the clinical outcomes of ALL patients with different germline variants of GATA3 that are commonly seen in Ph-like ALL is unknown. Methods: Of the newly diagnosed patients treated at MD Anderson Cancer Center (MDACC) with B-ALL, we performed analyses for the GATA3 rs3824662 variant in 85 patients (42 Ph-like ALL, 43 non-Ph-like ALL). Testing for Ph-like ALL, CRLF2 rearrangement, and GATA3 genotypes was performed as previously described (Jain, ASH 2017). Results: Of the 85 patients, the rs3824662 AA genotype was identified in 22 patients, the AC genotype in 33 patients, and the CC genotype in 29 patients. There was a trend towards increased frequency of Hispanic heritage in the AA genotype (86%) vs AC genotype (61%), vs the CC genotype (31%). Additionally, amongst patients with the AA genotype, 91% had the Ph-like ALL vs 45% of the AC genotype vs 10% of the CC genotype. The median white blood count at diagnosis was 52.1 x 109/L in the AA genotype group, 20 x 109/L in the AC genotype group, and 5.9 x 109/L in the CC genotype group. The 5 year event-free-survival (EFS) of the CC group was 55% vs 36% of the AC group vs 14% of the AA group. The EFS between the 3 genotypic groups was statistically significant with a p value of 0.018. The 5 year overall survival (OS) of the CC group was 64% vs 42% of the AC group vs 14% of the AA group. Conclusions: We observed significant differences in the EFS between patients with 0, 1, 2 copies of this genetic polymorphism in the GATA3 gene. The role of genomic AA GATA3 variant on the biology of ALL and understanding of the downstream mechanisms needs to be determined. [Table: see text]

caBIG: Proof of concept platform for personalized cancer care

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e20712-e20712
Author(s):  
K. Buetow
Keyword(s):  
Clinical Outcomes ◽  
Collaborative Research ◽  
Clinical Care ◽  
Cancer Center ◽  
Proof Of Concept ◽  
Collective Knowledge ◽  
Drug Discovery And Development ◽  
Share Data ◽  
Essential Unity ◽  
Personalized Cancer

e20712 Background: Numerous factors including enhanced understanding of the molecular basis of disease and the availability of sophisticated information technology are catalyzing a “rapid learning healthcare system,” where knowledge obtained from clinical outcomes can drive research discoveries that can be can be brought rapidly to the bedside. Benefits from such an iterative process may include earlier detection, more efficient drug discovery and development, and individualized patient care leading to better clinical outcomes. Methods: The National Cancer Institute (NCI) identified the need for an informatics initiative in recognition of the growing clinical and economic burden of cancer; the transformation of research catalyzed by multiple genomics technologies that were generating massive amounts of data; and recognition that the “essential unity” of research and clinical care had powerful potential to improve the outcomes of all cancers, as it had done in the field of pediatric oncology. In response, NCI pioneered caBIG (cancer Biomedical Informatics Grid), a network of interconnected data, individuals, and organizations, designed to share data and knowledge, simplify collaboration, and speed research. Results: caBIG is being deployed and used in numerous research and clinical facilities, including almost 60 NCI-designated cancer centers and the NCI's National Community Cancer Center Program (NCCCP). This widespread implementation provides the framework for collaborative research projects and data sharing that will accelerate basic and clinical research and improve clinical care. Programs enabled by caBIG technologies are included in the table . Conclusions: The benefits of an interconnected cancer community will multiply as the collective knowledge and expertise of its members is harnessed and their findings are shared. Researchers and clinicians must be fully aware of opportunities to connect data, individuals and institutions to achieve their goals. [Table: see text] No significant financial relationships to disclose.

Providers' concordance with survivorship clinical algorithms.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e20645-e20645
Author(s):  
Frances Ann Zandstra ◽  
Guadalupe R. Palos ◽  
Ludivine Russell ◽  
Katherine R. Gilmore ◽  
Jacklyn J. Flores ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Disease Surveillance ◽  
Clinical Care ◽  
Future Research ◽  
X Rays ◽  
Care Plans ◽  
Minimum Standards ◽  
Life Style Changes ◽  
Late Treatment ◽  
The Impact

e20645 Background: The utility of algorithms to guide clinical practice related to long-term survivorship care is unclear. In 2012, lymphoma survivorship algorithms for Hodgkin’s and Large B-Cell were developed as part of an institutional clinical practice initiative to enhance survivors’ outcomes. Here we describe providers’ concordance with minimum standards recommended in survivorship lymphoma algorithms. Methods: Concordance, the primary outcome, was defined as whether minimum recommendations, summarized in lymphoma algorithms, were provided during a survivorship visit. Concordance was measured using a “yes/no” response format assessing whether a provider’s recommendations were consistent with algorithms’ minimum standards including: 1) physical examination, 2) laboratory and imaging testing, 3) cancer screening procedures, and 4) health promotion education. Data were abstracted from electronic medical records and Passports (summary care plans). Secondary outcomes were number of survivors seen and Passports issued. All data included in these analyses were de-identified. Results: From 05/01 to 09/30/2012, all 63 survivors seen in the Lymphoma Survivorship Clinic received a Passport. Providers individualized Passports based on a survivor’s needs relevant to disease surveillance, life-style changes, screening recommendations, and specific procedures to assess for a recurrence or late treatment effects. Results indicated 100% of survivors received a physical exam, adult vaccinations, and cardiovascular screening. Similar rates were achieved for CBC testing, chest X-rays, assessing survivors’ psychosocial distress, and counseling survivors on screening recommendations specific to breast, cervical, colorectal and prostate cancers. Additionally, rates for skin exam recommendations were 97%. Conclusions: Based on concordance results, providers met the minimum recommendations listed in the lymphoma algorithms. Future research is needed to assess the impact of providers’ use of algorithms on survivors’ outcomes and feasibility of replicating concordance analyses in other clinical care settings.

scholarly journals 280 Clinical outcomes of immunotherapy continued beyond radiographic progression in older adults with advanced non-small cell lung cancer

2021 ◽  
Vol 9 (Suppl 3) ◽  
pp. A304-A304
Author(s):  
Eric Singhi ◽  
Frank Mott ◽  
Michelle Worst ◽  
Cheuk Hong Leung ◽  
Jack Lee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Older Adults ◽  
Clinical Outcomes ◽  
Median Duration ◽  
Advanced Nsclc ◽  
Cancer Center ◽  
University Of Texas ◽  
Grade 3 ◽  
Md Anderson ◽  
The University

BackgroundWhile the clinical outcomes of immune checkpoint inhibitor (ICI) use in older adults with advanced-stage non-small cell lung cancer (NSCLC) have been described, the role of ICI use continued beyond disease progression (BDP) remains to be well defined for this population. This retrospective single-center study explored the clinical outcomes of continuing ICIs BDP among older adult patients with advanced NSCLC.MethodsUsing MD Anderson’s Gemini Lung Cancer database, we retrospectively reviewed the clinical outcomes of older adults (≥70 years) diagnosed with advanced-stage NSCLC treated with anti-PD-(L)1 monotherapy from March 2015 through April 2019 to correlate clinicopathologic features with clinical outcomes. Clinical therapy responses were evaluated by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1). Toxicities were assessed using Common Terminology Criteria for Adverse Events (CTCAE), version 5. Patients treated BDP were defined as individuals receiving ICIs for ≥8 weeks prior to documentation of progression who subsequently remained on ICIs for ≥6 weeks.ResultsOf the 159 older adults meeting the inclusion criteria, 33 (21%) received ICIs BDP (64% male, median age 74.9 years (70.1–82.0) at the start of ICI treatment, 3 received first-line ICI therapy). Most patients were former (85%) or current (6%) smokers. 79% had adenocarcinoma histology. The median duration of immunotherapy continued BDP was 7.1 months (95% CI: 3.0–8.2). After a follow-up of 30.1 months, the median overall survival (mOS) was 31.5 months (95% CI: 16.5-not reached). Eight (24%) received local consolidative radiotherapy with a median duration of ICI BDP of 8.2 months (95% CI: 1.9–13.3). Twenty-five (76%) did not receive local consolidative therapy and achieved a median duration of ICI BDP of 4.1 months (95% CI: 2.3–7.8). Six (18%) exhibited pseudo-progression (i.e. delayed response to immunotherapy with decreased tumor burden on subsequent radiologic studies), with 4 achieving ”stable disease” as best response and 2 achieving a partial response. The median duration of immunotherapy continued beyond pseudo-progression was 11.7 months (95% CI: 7.1–35.7), and the mOS was 26.2 months (95% CI: 16.5–40.0). Patients treated with ICI BDP most commonly experienced fatigue (18%), pneumonitis (12%), rash (9%), and hypothyroidism (9%). Three patients (9%) experienced grade 3 or higher toxicities (one grade 3 arthralgias and two grade 3 pneumonitis).ConclusionsICI-use BDP in older adults with advanced NSCLC may benefit a subset of patients. Additionally, local consolidative therapy with radiation may offer prolonged duration of ICI treatment.AcknowledgementsSupported by the generous philanthropic contributions to The University of Texas MD Anderson Lung Moon Shot Program and the MD Anderson Cancer Center Support Grant P30 CA01667. Special acknowledgment to the GEMINI team.Ethics ApprovalThis study was approved and conducted in accordance with the institutional review board at the University of Texas MD Anderson Cancer Center; approval number (PA13-0589).

scholarly journals Use of clinical care registries to facilitate research study recruitment.

2013 ◽  
Vol 31 (31_suppl) ◽  
pp. 129-129
Author(s):  
Karen Messer ◽  
Tracy M. Layton ◽  
Tony Chen ◽  
Viswanath Nandigam ◽  
Katherine Abihider ◽  
...  
Keyword(s):  
Breast Imaging ◽  
Clinical Care ◽  
Menopausal Status ◽  
Cancer Center ◽  
Future Research ◽  
Care Clinic ◽  
Research Opportunities ◽  
Patient Reported ◽  
Breast Care ◽  
Research Studies

129 Background: We developed IRB-approved secure research registries for our Breast Imaging and Breast Care Clinics at Moores UC San Diego Cancer Center, as part of the UC statewide Athena Breast Health Network. Our clinical care registries securely store patient-reported intake data, which are summarized and uploaded into the medical record for patient care. Following consent, data are securely maintained in a separate research registry. In addition to facilitating quality assurance data collection, these registries aim to 1) maintain a data-rich research registry, 2) offer patients research opportunities, and 3) facilitate participant screening and recruitment into research studies. Methods: Breast Imaging or Breast Care clinic patients complete an online clinical intake form prior to their appointment, either at home or using an iPad in clinic, and are given the opportunity to be involved in research. Patients are asked for site-specific consent to keep personally identifiable intake data in a research registry, for consent to be approached about providing a biospecimen sample, and for consent to be contacted for future research opportunities. Data from consented participants are pulled into secure databases available to study personnel. Results: Participants to date include 4,480 patients, of whom 3,246 consented to use of data for research (72%), and 2,627 have agreed to be contacted for future research opportunities (59%). In a pilot biospecimen collection protocol, 46% of patients agreed to be approached and we have collected over 360 blood or saliva and 51 tissue samples. Additionally, with the use of future contact consent, we have facilitated recruitment of more than 370 participants to multiple lifestyle and survey-based clinical studies. Conclusions: Patients are willing to participate in research, especially in a research registry that requires little additional time on their part. The use of research registries allows collection of a variety of data elements useful for prescreening participants for research studies, including body mass index, age, menopausal status and breast cancer diagnosis. Data- and participant-rich research registries facilitate efficient screening and recruitment for other research studies.

Providers' concordance with survivorship clinical algorithms.

2014 ◽  
Vol 32 (31_suppl) ◽  
pp. 243-243
Author(s):  
Frances Ann Zandstra ◽  
Guadalupe R. Palos ◽  
Ludivine Russell ◽  
Katherine Ramsey Gilmore ◽  
Jacklyn J. Flores ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Disease Surveillance ◽  
Clinical Care ◽  
Future Research ◽  
X Rays ◽  
Care Plans ◽  
Minimum Standards ◽  
Life Style Changes ◽  
Late Treatment ◽  
The Impact

243 Background: The utility of algorithms to guide clinical practice related to long-term survivorship care is unclear. In 2012, lymphoma survivorship algorithms for Hodgkin’s and Large B-Cell were developed as part of an institutional clinical practice initiative to enhance survivors’ outcomes. Here we describe providers’ concordance with minimum standards recommended in the survivorship lymphoma algorithm. Methods: Concordance, the primary outcome, was defined as whether minimum recommendations, summarized in the lymphoma algorithms, were provided during a survivorship visit. Concordance was measured using a “yes/no” response format assessing whether a provider’s recommendations were consistent with algorithms’ minimum standards including: 1) physical examination, 2) laboratory and imaging testing, 3) cancer screening procedures, and 4) health promotion education. Data were abstracted from electronic medical records and Passports (summary care plans). Secondary outcomes were number of survivors seen and Passports issued. All data included in these analyses were de-identified. Results: 63 survivors were seen in the Lymphoma Survivorship Clinic from 05/01 to 09/30/2012 and all received Passports. A provider tailored the plan to each survivor’s needs and counseled the individual on disease surveillance, life-style changes, screening recommendations, and specific procedures to assess for recurrence/late treatment effects. Results indicated 100% of survivors received a physical exam, including cardiovascular screening. Similar rates were also achieved for CBC testing, chest X-rays, and counseling survivors on screening recommendations relevant to: breast, cervical, colorectal and prostate cancers. Other counseling rates included 97% for skin exam recommendations and 100% for maintaining adult vaccinations. Finally, providers’ concordance with assessment of survivors’ psychosocial distress was 100%. Conclusions: Based on concordance results, providers met the minimum recommendations listed in the lymphoma algorithms. Future research is needed to assess the impact of providers’ use of algorithms on survivors’ outcomes and feasibility of replicating concordance analyses in other clinical care settings.

Sign in / Sign up

Export Citation Format

Share Document